ReviewNature reviews. Nephrology2011
Statins, inflammation and kidney disease.
Review in Nature reviews. Nephrology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 97 citations in OpenAlex.
- Statins Have an Anti-Inflammation in CKD Patients: A Meta-Analysis of Randomized Trials.BioMed research international · 2022Pooled it
- Circulating fatty acid profiles are associated with protein energy wasting in maintenance hemodialysis patients: a cross-sectional study.Scientific reports · 2021Trial
- Trial
- Rosuvastatin preserves renal function and lowers cystatin C in HIV-infected subjects on antiretroviral therapy: the SATURN-HIV trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014Trial
- Explainable machine learning integrating biochemical and metabolomic biomarkers with conventional clinical factors improves chronic kidney disease prediction and risk stratification.BMC nephrology · 2026Article
- Patient-related factors that link chronic kidney disease and periodontitis: a scoping review.Odontology · 2025Article
- The Prognostic Impact of Kidney Dysfunction in Unselected Patients Undergoing Coronary Angiography: In What Subgroups Does Kidney Dysfunction Matter?Journal of clinical medicine · 2025Article
- Ultrasound combined with microbubble enhanced renoprotective effects of NLRP3 inflammasome inhibitor MCC950 in CKD model.Frontiers in pharmacology · 2025Article
- Association between Monocyte-to-Lymphocyte Ratio and Inflammation in Chronic Kidney Disease: A Cross-Sectional Study.Kidney & blood pressure research · 2024Article
- Cardiovascular Disease in Diabetes and Chronic Kidney Disease.Journal of clinical medicine · 2023Review
- The Clinical Significance of LDL-Cholesterol on the Outcomes of Hemodialysis Patients with Acute Coronary Syndrome.Medicina (Kaunas, Lithuania) · 2023Article
- Biomarker and genomic analyses reveal molecular signatures of non-cardioembolic ischemic stroke.Signal transduction and targeted therapy · 2023Article
- International practice patterns of dyslipidemia management in patients with chronic kidney disease under nephrology care: is it time to review guideline recommendations?Lipids in health and disease · 2023Article
- Systemic Immune-Inflammation Index Was Significantly Associated with All-Cause and Cardiovascular-Specific Mortalities in Patients Receiving Peritoneal Dialysis.Journal of inflammation research · 2023Article
- Signaling pathways of chronic kidney diseases, implications for therapeutics.Signal transduction and targeted therapy · 2022Review
- Pericoronary fat attenuation index in computed tomography angiography is associated with mortality in end-stage renal disease.Kidney research and clinical practice · 2022Article
- Epicardial adipose tissue radiodensity is associated with all-cause mortality in patients undergoing hemodialysis.Scientific reports · 2021Article
- Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities.Nature reviews. Rheumatology · 2021Review
- Cardiovascular and Renal Disease in Chronic Critical Illness.Journal of clinical medicine · 2021Review
- Significance of Levocarnitine Treatment in Dialysis Patients.Nutrients · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation is highly prevalent in patients with chronic kidney disease (CKD) and is consistently associated with cardiovascular morbidity and mortality. Clinical event rates increase with declining renal function and activation of the acute-phase response. Statins are potent anti-inflammatory drugs that reduce the incidence of cardiovascular events. Owing to the increased prevalence of inflammation in patients with CKD and the potent effect of statins in individuals with elevated levels of C-reactive protein, these drugs should be especially effective in patients with CKD. Whereas data indicate that pravastatin may prevent loss of kidney function to a greater extent in individuals with evidence of increased inflammation than in those who show no inflammation, two large, randomized statin trials in patients on hemodialysis found no benefit of statin therapy, neither in the whole study group nor after stratifying for inflammation. Irrespective of inflammation, guidelines recommend treatment of dyslipidemia in early stages of CKD, which is supported by results from recent meta-analyses, and the Study of Heart and Renal Protection (SHARP), a large, randomized, placebo-controlled trial.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.